Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended
Oct. 31, 2011
Oct. 31, 2010
Revenues:    
Clinical laboratory services $ 14,187 $ 12,390
Product revenues 9,704 10,184
Royalty and license fee income 1,862 3,078
25,753 25,652
Operating expenses:    
Cost of clinical laboratory services 8,814 7,573
Cost of product revenues 5,137 4,606
Research and development 1,625 1,757
Selling, general, and administrative 12,385 11,032
Provision for uncollectible accounts receivable 1,286 1,075
Legal 868 696
Total operating expenses 30,115 26,739
Operating loss (4,362) (1,087)
Other income (expense):    
Interest (2) 5
Other 9 14
Foreign currency gain 29 8
Loss before income taxes (4,326) (1,060)
Provision for income taxes (168) (62)
Net loss $ (4,494) $ (1,122)
Net loss per common share:    
Basic and diluted (in Dollars per share) $ (0.12) $ (0.03)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 38,597 38,160